Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627675 · ClinicalTrials.gov registry record · Phase 1
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
A Phase 1 study, sponsored by Providence Health & Services.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04627675 is a Phase 1 study that was terminated before completion, run by Providence Health & Services. The registered enrollment target is 16 participants.
The verdict
NCT04627675, a Phase 1 study, was terminated before completion, sponsored by Providence Health & Services.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the combination of electroporated IL-12p70 plasmid.
Interventions
- DRUG CORVax
- DRUG IL-12 plasmid
- DEVICE Cliniporator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-30 |
| Est. Completion | 2022-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04627675
The ClinicalTrials.gov registry entry for NCT04627675 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CORVax is the first listed.
NCT04627675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04627675 about?
NCT04627675 is a clinical study titled "CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)". This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the combination of electroporated IL-12p70 plasmid.
What is the current status of trial NCT04627675?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-12-30. Estimated completion is 2022-12-28.
What interventions are being tested in trial NCT04627675?
The interventions under investigation include: CORVax (DRUG), IL-12 plasmid (DRUG), Cliniporator (DEVICE).
Who is sponsoring clinical trial NCT04627675?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.